Compare · head to head
Hikma Pharmaceuticals vs Novartis
Hikma Pharmaceuticals ranks higher overall — 360 rank 47 vs 38.
Hikma Pharmaceuticals leads on Value (81 vs 51) and Sentiment (46 vs 39). Novartis leads on Quality (65 vs 45) and Growth (37 vs 31). The two are close on Safety.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | UK | Switzerland |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | Large | XX-Large |
| ISIN | GB00B0LCW083 | CH0012005267 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 47 | 38 |
| Value | 81 | 51 |
| Quality | 45 | 65 |
| Growth | 31 | 37 |
| Safety | 43 | 44 |
| Sentiment | 46 | 39 |
| Quality details | ||
| Profitability | 53 | 76 |
| Cash Truth | 36 | 55 |
Hikma Pharmaceuticals vs Sol-Gel TechnologiesHikma Pharmaceuticals vs HaleonHikma Pharmaceuticals vs SandozHikma Pharmaceuticals vs EvotecAdd a third stock →
Full analyses: Hikma Pharmaceuticals · Novartis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100